How J&J Scientist Koul Hopes To Reboot R&D At India’s IMTECH
Anil Koul, part of the Johnson & Johnson team that discovered and developed TB drug Sirturo, is currently on a sabbatical to head up IMTECH, an Indian R&D institute. Koul shares with Scrip the ups and downs of Sirturo's development journey and outlines what he hopes to achieve at IMTECH.
You may also be interested in...
Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.
India has introduced Janssen's Sirturo, a poster child in the war against multidrug-resistant tuberculosis, through its Revised National Tuberculosis Control Program.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.